Literature DB >> 16428982

Time-resolved contrast enhanced magnetic resonance angiography of the head and neck at 3.0 tesla: initial results.

Kambiz Nael1, Henrik J Michaely, Pablo Villablanca, Noriko Salamon, Gerhard Laub, J Paul Finn.   

Abstract

OBJECTIVES: We sought to implement and evaluate a high-performance, extended field of view protocol for time-resolved contrast-enhanced magnetic resonance imaging (CEMRA) of the carotid circulation by using a dedicated neurovascular (NV) array coil.
MATERIALS AND METHODS: A total of 16 adult volunteers and 20 clinical patients with suspected cerebrovascular disease (15 male, 21 female, 25-82 years of age) were scanned with a fast 3D MRA sequence (TR/TE: 2.16/1 milliseconds, sampling BW: 1090 Hz/pixel), with echo-sharing and parallel acquisition. All studies were performed on a 3.0 T MR system using an 8-channel neurovascular array coil. After injection of 6 mL of gadodiamide at 3 mL/s, a coronal 3D data set with in-plane resolution of 1 x 1.3 was implemented for 10 consecutive measurements each 1.8 seconds apart. The subjects subsequently underwent high spatial-resolution (in-plane: 0.8 x 0.9) CEMRA for comparative analysis. The quality of segmental arterial anatomy and the presence and degree of the arterial stenosis were evaluated by 2 neuroradiologists. The interobserver variability was tested by kappa statistics and comparative analysis between the TR-CEMRA and high spatial-resolution CEMRA was evaluated by mean of the Spearman rank correlation coefficient.
RESULTS: Craniocervical arteries were visualized with good image quality and definition in the diagnostic range. Occlusive disease was detected in 42 (reader A) and 44 (reader B) arterial segments with excellent interobserver agreement (kappa =0.89; 95% confidence interval 0.82-0.96). There was a significant correlation between the TR-CEMRA and high spatial-resolution CEMRA (Rs = 0.91 and 0.93, for readers A and B, respectively) for the degree of stenosis. Three aneurysms, 3 AVMs, 1 AV-fistula, and 2 subclavian steals were detected by both observers and were confirmed by correlative imaging.
CONCLUSION: Time-resolved CEMRA at 3.0 T is reliable and versatile, providing 3-dimensional time-resolved data sets with high spatial (in plane: 1.3 x 1 mm2) and temporal (1.8 seconds) resolution over a large field of view. The higher signal-to-noise ratio gain at 3.0 T can be used effectively to improve performance of fast imaging and to support aggressive parallel acquisition protocols, as in the present study. Further clinical studies are required to establish the range of applications and the accuracy of the technique.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16428982     DOI: 10.1097/01.rli.0000192416.19801.ca

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  19 in total

1.  Quality-evaluation scheme for cerebral time-resolved 3D contrast-enhanced MR angiography techniques.

Authors:  H Raoult; J-C Ferré; X Morandi; B Carsin-Nicol; M Carsin; M Cuggia; M Law; J-Y Gauvrit
Journal:  AJNR Am J Neuroradiol       Date:  2010-05-06       Impact factor: 3.825

2.  Contrast-enhanced MR angiography at 3T in the evaluation of intracranial aneurysms: a comparison with time-of-flight MR angiography.

Authors:  K Nael; J P Villablanca; R Saleh; W Pope; A Nael; G Laub; J P Finn
Journal:  AJNR Am J Neuroradiol       Date:  2006 Nov-Dec       Impact factor: 3.825

3.  Accelerated time-resolved 3D contrast-enhanced MR angiography at 3T: clinical experience in 31 patients.

Authors:  Alex Frydrychowicz; Thorsten A Bley; Jan T Winterer; Andreas Harloff; Mathias Langer; Jürgen Hennig; Michael Markl
Journal:  MAGMA       Date:  2006-08-26       Impact factor: 2.310

4.  3D time-resolved MR angiography (MRA) of the carotid arteries with time-resolved imaging with stochastic trajectories: comparison with 3D contrast-enhanced Bolus-Chase MRA and 3D time-of-flight MRA.

Authors:  R P Lim; M Shapiro; E Y Wang; M Law; J S Babb; L E Rueff; J S Jacob; S Kim; R H Carson; T P Mulholland; G Laub; E M Hecht
Journal:  AJNR Am J Neuroradiol       Date:  2008-09-03       Impact factor: 3.825

5.  3D time-resolved contrast-enhanced cerebrovascular MR angiography with subsecond frame update times using radial k-space trajectories and highly constrained projection reconstruction.

Authors:  Y Wu; N Kim; F R Korosec; A Turk; H A Rowley; O Wieben; C A Mistretta; P A Turski
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-10       Impact factor: 3.825

6.  Recent advances in 3D time-resolved contrast-enhanced MR angiography.

Authors:  Stephen J Riederer; Clifton R Haider; Eric A Borisch; Paul T Weavers; Phillip M Young
Journal:  J Magn Reson Imaging       Date:  2015-06-01       Impact factor: 4.813

7.  Noncontrast enhanced four-dimensional dynamic MRA with golden angle radial acquisition and K-space weighted image contrast (KWIC) reconstruction.

Authors:  Hee Kwon Song; Lirong Yan; Robert X Smith; Yiqun Xue; Stanislas Rapacchi; Subashini Srinivasan; Daniel B Ennis; Peng Hu; Nader Pouratian; Danny J J Wang
Journal:  Magn Reson Med       Date:  2013-12-12       Impact factor: 4.668

Review 8.  [Chronic critical ischemia of the lower leg: pretherapeutic imaging and methods for revascularization].

Authors:  M Treitl; V Ruppert; A K Mayer; C Degenhart; M Reiser; J Rieger
Journal:  Radiologe       Date:  2006-11       Impact factor: 0.635

9.  Time-resolved MR angiography: optimal parallel imaging method.

Authors:  J-Y Gauvrit; M Law; J Xu; R Carson; P Sunenshine; Q Chen
Journal:  AJNR Am J Neuroradiol       Date:  2007-05       Impact factor: 3.825

10.  Three-dimensional contrast-enhanced magnetic-resonance angiography of the renal arteries: interindividual comparison of 0.2 mmol/kg gadobutrol at 1.5 T and 0.1 mmol/kg gadobenate dimeglumine at 3.0 T.

Authors:  Ulrike I Attenberger; Henrik J Michaely; Bernd J Wintersperger; Steven P Sourbron; Klaus-Peter Lodemann; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Eur Radiol       Date:  2008-02-16       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.